The Fly | SI

Over a week ago

Shoulder Innovations raises FY26 revenue view to $65M-$68M from $62M-$65M

May 13, 4:11 PM

Shoulder Innovations reports Q1 EPS (41c), consensus (43c)

May 13, 4:10 PM

Shoulder Innovations price target raised by $1 at Piper Sandler, here's why

May 8, 7:08 AM

Private Markets: Musk tightens grip at SpaceX, Sierra hits $15B valuation

+31

May 7, 2:29 PM

Shoulder Innovations price target raised by $1 at BTIG, here's why

Mar 11, 7:22 AM

Shoulder Innovations sees FY26 revenue $62M-$65M, consensus $58.77M

Mar 10, 4:22 PM

Shoulder Innovations reports Q4 EPS (38c), consensus (38c)

Mar 10, 4:21 PM

Shoulder Innovations price target raised by $1 at Goldman Sachs, here's why

Jan 9, 5:51 AM

Shoulder Innovations partners with INS for robotic surgical platform

Dec 3, 7:08 AM

Shoulder Innovations price target raised by $5 at Morgan Stanley, here's why

Dec 2, 6:34 AM

Closing Bell Movers: AMD up 5% after unveiling medium term targets

+13

Nov 11, 7:03 PM

Shoulder Innovations raises FY25 revenue view to $45M-$46M from $42M-$44M

Nov 11, 4:12 PM

Shoulder Innovations reports Q3 EPS (64c), consensus (37c)

Nov 11, 4:10 PM

Shoulder Innovations receives 510(k) Premarket Notification for shoulder system

Sep 30, 12:15 PM

Shoulder Innovations reports Q2 EPS ($165.53) vs. ($72.74) last year

Sep 9, 7:03 AM

Figma initiated, Okta upgraded: Wall Street's top analyst calls

+12

Aug 25, 9:36 AM

Shoulder Innovations initiated with bullish view at Morgan Stanley, here's why

Aug 25, 8:01 AM

Shoulder Innovations initiated with bullish view at Jefferies, here's why

Aug 25, 5:02 AM

Shoulder Innovations initiated with bullish view at Piper Sandler, here's why

Aug 25, 4:56 AM

Shoulder Innovations initiated with bullish view at Goldman Sachs, here's why

Aug 25, 4:25 AM

Shoulder Innovations 5M share IPO priced at $15.00

Jul 31, 6:01 AM

Shoulder Innovations 5M share IPO price range $19.00-$21.00

Jul 24, 11:09 AM

No more stories

Unique Bone-Preserving Technology: The InSet™ Glenoid system offers a unique, universally sized, and bone-preserving implant design, minimizing bone resection and potentially improving long-term outcomes compared to traditional keeled or pegged glenoids.

Enhanced Clinical Stability and Longevity: Their InSet™ Glenoid technology is engineered to provide superior initial stability and reduced micromotion, contributing to improved long-term clinical performance and lower rates of glenoid loosening.

Streamlined Surgical Workflow: The universal sizing and simplified instrumentation of the InSet™ system streamline the surgical procedure, reduce inventory complexity for hospitals, and enhance reproducibility across diverse patient anatomies.

Regulatory Approval Delays: Risk of not obtaining timely or full regulatory approvals from bodies like the FDA for new products or modifications, hindering market access.

Product Liability Claims: Risk of facing lawsuits and significant financial penalties due to device malfunction, patient injury, or alleged design defects.

Intense Market Competition: Risk of difficulty gaining or maintaining market share due to strong competition from well-established orthopedic medical device companies.